Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors
Masayuki Takeda(Kindai University), Kazuto Nishio(Kindai University Sakai Hospital), Shigeki Shimizu(Kindai University), Kazuko Sakai(Kindai University Sakai Hospital), Soichi Fumita(Kindai University), Chihiro Sato(Washington University in St. Louis), Hidetoshi Hayashi(Kindai University), Kimio Yonesaka(Kindai University), Naoki Takegawa(Hyogo Prefectural Cancer Center), Shinichiro Suzuki(Kindai University), Kazumasa Saigoh(Kindai University Hospital), Satomi Watanabe(Kindai University), Koji Haratani(Dana-Farber Cancer Institute), Tatsuya Okuno(Kindai University), Takayuki Takahama(Kindai University), Akihiko Ito(Kobe University), Tetsuya Mitsudomi(Kindai University), Hisashi Handa(Okayama University), Takeshi Yoshida(Kanazawa University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Kaoru Tanaka(Kindai University), Yoshikane Nonagase(Kindai University), Kazuya Fukuoka(Kindai University), Hisato Kawakami(Tohoku University)
Cited by 95
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k